Succinate Dehydrogenase-deficient Gastrointestinal Stromal Tumors

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2015 Mar 6

PMID 25741136

Citations 22

Authors

Ya-Mei Wang

Meng-Li Gu

Feng Ji

Affiliations

Soon will be listed here.

Abstract

Most gastrointestinal stromal tumors (GISTs) are characterized by KIT or platelet-derived growth factor alpha (PDGFRA) activating mutations. However, there are still 10%-15% of GISTs lacking KIT and PDGFRA mutations, called wild-type GISTs (WT GISTs). Among these so-called WT GISTs, a small subset is associated with succinate dehydrogenase (SDH) deficiency, known as SDH-deficient GISTs. In addition, GISTs that occur in Carney triad and Carney-Stratakis syndrome represent specific examples of SDH-deficient GISTs. SDH-deficient GISTs locate exclusively in the stomach, showing predilection for children and young adults with female preponderance. The tumor generally pursues an indolent course and exhibits primary resistance to imatinib therapy in most cases. Loss of succinate dehydrogenase subunit B expression and overexpression of insulin-like growth factor 1 receptor (IGF1R) are common features of SDH-deficient GISTs. In WT GISTs without succinate dehydrogenase activity, upregulation of hypoxia-inducible factor 1α may lead to increased growth signaling through IGF1R and vascular endothelial growth factor receptor (VEGFR). As a result, IGF1R and VEGFR are promising to be the novel therapeutic targets of GISTs. This review will update the current knowledge on characteristics of SDH-deficient GISTs and further discuss the possible mechanisms of tumorigenesis and clinical management of SDH-deficient GISTs.

Citing Articles

Biallelic inactivation of results in comorbidity of pediatric recurrent neuroblastoma and gastric stromal tumor.

Yang S, Zhang S, Zhao W, Fu L, Zhang L, Chui C Genes Dis. 2024; 11(6):101196.

PMID: 39464303 PMC: 11512112. DOI: 10.1016/j.gendis.2023.101196.

Pan-Canadian consensus recommendations for GIST management in high- and low-throughput centres across Canada.

Beecroft J, Brar S, Feng X, Hamilton T, Han-Lee C, Henning J Ther Adv Med Oncol. 2024; 16:17588359241266179.

PMID: 39386314 PMC: 11461906. DOI: 10.1177/17588359241266179.

Advancing Precision Oncology in Hereditary Paraganglioma-Pheochromocytoma Syndromes: Integrated Interpretation and Data Sharing of the Germline and Tumor Genomes.

Rana H, Koeller D, Walker M, Unal B, Levine A, Chittenden A Cancers (Basel). 2024; 16(5).

PMID: 38473309 PMC: 10931192. DOI: 10.3390/cancers16050947.

Longitudinal Natural History Study of Children and Adults with Rare Solid Tumors: Initial Results for First 200 Participants.

Ahmed S, Wedekind M, Del Rivero J, Raygada M, Lockridge R, Glod J Cancer Res Commun. 2023; 3(12):2468-2482.

PMID: 37966258 PMC: 10699159. DOI: 10.1158/2767-9764.CRC-23-0247.

From KIT-mutated into wild-type: dedifferentiation of gastrointestinal stromal tumor in adolescent patient-a case report.

Andrzejewska M, Czarny J, Skalska-Sadowska J, Jonczyk-Potoczna K, Kurzawa P, Wichtowski M J Gastrointest Oncol. 2023; 14(4):1887-1893.

PMID: 37720439 PMC: 10502532. DOI: 10.21037/jgo-22-1111.

References

Gill A, Chou A, Vilain R, Clarkson A, Lui M, Jin R . Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am J Surg Pathol. 2010; 34(5):636-44. DOI: 10.1097/PAS.0b013e3181d6150d. View

Lasota J, Wang Z, Kim S, Helman L, Miettinen M . Expression of the receptor for type i insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications. Am J Surg Pathol. 2012; 37(1):114-9. PMC: 3502638. DOI: 10.1097/PAS.0b013e3182613c86. View

Janeway K, Kim S, Lodish M, Nose V, Rustin P, Gaal J . Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A. 2010; 108(1):314-8. PMC: 3017134. DOI: 10.1073/pnas.1009199108. View

Sell C, Dumenil G, Deveaud C, Miura M, Coppola D, DeAngelis T . Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol. 1994; 14(6):3604-12. PMC: 358728. DOI: 10.1128/mcb.14.6.3604-3612.1994. View

Agaimy A, Wunsch P . Lymph node metastasis in gastrointestinal stromal tumours (GIST) occurs preferentially in young patients < or = 40 years: an overview based on our case material and the literature. Langenbecks Arch Surg. 2008; 394(2):375-81. DOI: 10.1007/s00423-008-0449-5. View

Kim E, Zalupski M . Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib. J Surg Oncol. 2011; 104(8):901-6. DOI: 10.1002/jso.21872. View

Miettinen M, Wang Z, Sarlomo-Rikala M, Osuch C, Rutkowski P, Lasota J . Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol. 2011; 35(11):1712-21. PMC: 3193596. DOI: 10.1097/PAS.0b013e3182260752. View

Stratakis C, Carney J . The triad of paragangliomas, gastric stromal tumours and pulmonary chondromas (Carney triad), and the dyad of paragangliomas and gastric stromal sarcomas (Carney-Stratakis syndrome): molecular genetics and clinical implications. J Intern Med. 2009; 266(1):43-52. PMC: 3129547. DOI: 10.1111/j.1365-2796.2009.02110.x. View

Dahia P, Ross K, Wright M, Hayashida C, Santagata S, Barontini M . A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 2005; 1(1):72-80. PMC: 1183527. DOI: 10.1371/journal.pgen.0010008. View

10.

Schmoldt A, BENTHE H, Haberland G . Digitoxin metabolism by rat liver microsomes. Biochem Pharmacol. 1975; 24(17):1639-41. View

11.

Gimenez-Roqueplo A, Favier J, Rustin P, Mourad J, Plouin P, Corvol P . The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet. 2001; 69(6):1186-97. PMC: 1235531. DOI: 10.1086/324413. View

12.

Joensuu H, Vehtari A, Riihimaki J, Nishida T, Steigen S, Brabec P . Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol. 2011; 13(3):265-74. DOI: 10.1016/S1470-2045(11)70299-6. View

13.

Pantaleo M, Astolfi A, Indio V, Moore R, Thiessen N, Heinrich M . SDHA loss-of-function mutations in KIT-PDGFRA wild-type gastrointestinal stromal tumors identified by massively parallel sequencing. J Natl Cancer Inst. 2011; 103(12):983-7. DOI: 10.1093/jnci/djr130. View

14.

Safran M, Kaelin Jr W . HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest. 2003; 111(6):779-83. PMC: 153778. DOI: 10.1172/JCI18181. View

15.

Scotlandi K, Picci P . Targeting insulin-like growth factor 1 receptor in sarcomas. Curr Opin Oncol. 2008; 20(4):419-27. DOI: 10.1097/CCO.0b013e328302edab. View

16.

Kaelin Jr W . The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008; 8(11):865-73. DOI: 10.1038/nrc2502. View

17.

Gualberto A, Pollak M . Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene. 2009; 28(34):3009-21. DOI: 10.1038/onc.2009.172. View

18.

Atkins M, Jones C, Kirkpatrick P . Sunitinib maleate. Nat Rev Drug Discov. 2006; 5(4):279-80. DOI: 10.1038/nrd2012. View

19.

Gill A, Chou A, Vilain R, Clifton-Bligh R . "Pediatric-type" gastrointestinal stromal tumors are SDHB negative ("type 2") GISTs. Am J Surg Pathol. 2011; 35(8):1245-7. DOI: 10.1097/PAS.0b013e3182217b93. View

20.

Gotlieb W, Bruchim I, Gu J, Shi Y, Camirand A, Blouin M . Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol. 2005; 100(2):389-96. DOI: 10.1016/j.ygyno.2005.09.048. View